Literature DB >> 20826060

Leptin: the link between overweight and primary hyperparathyroidism?

Shih-Ping Cheng1, Gerard M Doherty, Yuan-Ching Chang, Chien-Liang Liu.   

Abstract

Primary hyperparathyroidism is one of the most common causes of hypercalcemia. Most cases result from sporadic benign monoclonal adenomas or hyperplasia. Increased body weight is consistently present in cohorts of patients with primary hyperparathyroidism. It has been shown that fat mass is the major determinant of serum parathyroid hormone levels independent of vitamin D status. Leptin, an adipocyte-derived hormone with mitogenic activity, regulates energy homeostasis and mineral metabolism. Serum leptin levels increase in parallel to the amount of adipose stores. Interestingly, a positive association between leptin and parathyroid hormone levels is observed. Patients with primary hyperparathyroidism have higher serum leptin levels than healthy subjects. In addition, leptin administration in mice increases circulating levels of parathyroid hormone. We hypothesize that leptin involves pathogenesis of primary hyperparathyroidism and represents a link between hyperparathyroidism and increased body weight.
Copyright © 2010 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20826060     DOI: 10.1016/j.mehy.2010.08.039

Source DB:  PubMed          Journal:  Med Hypotheses        ISSN: 0306-9877            Impact factor:   1.538


  9 in total

Review 1.  Bone Remodeling and Energy Metabolism: New Perspectives.

Authors:  Francisco J A de Paula; Clifford J Rosen
Journal:  Bone Res       Date:  2013-03-29       Impact factor: 13.567

2.  An inverted U-shaped relationship between parathyroid hormone and body weight, body mass index, body fat.

Authors:  Tian-Jiao Yuan; Liu-Ping Chen; Ya-Ling Pan; Yong Lu; Li-Hao Sun; Hong-Yan Zhao; Wei-Qing Wang; Bei Tao; Jian-Min Liu
Journal:  Endocrine       Date:  2021-02-06       Impact factor: 3.633

Review 3.  The intriguing connections of leptin to hyperparathyroidism.

Authors:  Stergios A Polyzos; Leonidas Duntas; Jens Bollerslev
Journal:  Endocrine       Date:  2017-07-20       Impact factor: 3.633

4.  Leptin directly stimulates parathyroid hormone secretion.

Authors:  Ignacio Lopez; Carmen Pineda; Ana I Raya; Maria E Rodriguez-Ortiz; Juan M Diaz-Tocados; Rafael Rios; Juan M Rodriguez; Escolastico Aguilera-Tejero; Yolanda Almaden
Journal:  Endocrine       Date:  2016-12-16       Impact factor: 3.633

5.  Serum leptin, parathyroid hormone, 1,25-dihydroxyvitamin D, fibroblast growth factor 23, bone alkaline phosphatase, and sclerostin relationships in obesity.

Authors:  Elizabeth Grethen; Kathleen M Hill; RoseMarie Jones; Brenda M Cacucci; Christine E Gupta; Anthony Acton; Robert V Considine; Munro Peacock
Journal:  J Clin Endocrinol Metab       Date:  2012-02-22       Impact factor: 5.958

6.  Molecular pathways associated with transcriptional alterations in hyperparathyroidism.

Authors:  Fang Lee; Jie-Jen Lee; Woan-Ching Jan; Chih-Jen Wu; Han-Hsiang Chen; Shih-Ping Cheng
Journal:  Oncol Lett       Date:  2016-05-25       Impact factor: 2.967

7.  Negative association between serum parathyroid hormone levels and urinary perchlorate, nitrate, and thiocyanate concentrations in U.S. adults: the National Health and Nutrition Examination Survey 2005-2006.

Authors:  Wen-Ching Ko; Chien-Liang Liu; Jie-Jen Lee; Tsang-Pai Liu; Po-Sheng Yang; Yi-Chiung Hsu; Shih-Ping Cheng
Journal:  PLoS One       Date:  2014-12-16       Impact factor: 3.240

8.  Hypocaloric Diet Prevents the Decrease in FGF21 Elicited by High Phosphorus Intake.

Authors:  Carmen Pineda; Rafael Rios; Ana I Raya; Mariano Rodriguez; Escolastico Aguilera-Tejero; Ignacio Lopez
Journal:  Nutrients       Date:  2018-10-13       Impact factor: 5.717

9.  Association between neutrophil-to-lymphocyte ratio and parathyroid hormone in patients with primary hyperparathyroidism.

Authors:  Hung-Bun Lam; Po-Sheng Yang; Ming-Nan Chien; Jie-Jen Lee; Li-Fen Chao; Shih-Ping Cheng
Journal:  Arch Med Sci       Date:  2018-03-28       Impact factor: 3.318

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.